China-based Biotheus Inc. announced that its clinical trial filing for PM1009, a bispecific antibody (BsAb) targeting T cell immunoglobulin and ITIM domains (TIGIT) and poliovirus receptor related immunoglobulin domain (PVRIG), has been accepted by the Center for Drug Evaluation (CDE). The drug, co-developed with US firm Adimab, is aimed at treating solid tumors.
Preclinical Results
PM1009 has demonstrated high affinity binding to TIGIT and PVRIG proteins, effectively relieving immunosuppressive signals and enhancing CD226 activation. In PD-1 resistant mouse models, PM1009 combined with anti-PD-1 therapy showed superior anti-tumor activity compared to TIGIT or PVRIG mAbs alone. The GLP toxicology study confirmed a favorable safety profile.-Fineline Info & Tech
